Frederick G Vogt bought $42k of IOVA
Interim CEO & General Counsel at IOVANCE BIOTHERAPEUTICS, INC.. 25,000 shares at an average of $1.69, traded May 14, 2025, filed May 16, 2025.
Score components
- +25RoleCEO
- +6Trade size$42k at market
- +3Relative to holdingsHoldings up 7%
- +18Price context0% above the 52-week low; 86% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001104659-25-049999, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 14, 2025 | POpen-market purchase Common Stock | +25,000 | $1.69 | $42k | 374,646 | May 16, 2025 |
Related signals
Other insiders at IOVANCE BIOTHERAPEUTICS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Daniel Gordon Kirby Chief Commercial Officer | $55k 30,000 shares | - | |
| 48Moderate | IOVANCE BIOTHERAPEUTICS, INC. | Raj K. Puri Chief Regulatory Officer | $9,743 5,600 shares | +3% | |
| 38Weak | IOVAsell IOVANCE BIOTHERAPEUTICS, INC. | Ryan D Maynard director | $503k 50,000 shares | -87% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.